The Use of Biologics for Hip Preservation
Recommended Citation
Jildeh TR, Abbas MJ, Buckley P, and Okoroha KR. The Use of Biologics for Hip Preservation. Curr Rev Musculoskelet Med 2021.
Document Type
Article
Publication Date
1-23-2021
Publication Title
Curr Rev Musculoskelet Med
Abstract
PURPOSE OF REVIEW: A wide array of nonoperative modalities to treat hip pain are aimed at restoring and maintaining the structural and physiologic characteristics of the joint. The purpose of this review is to describe the current understanding of biologics in hip pathology by providing an evidence-based overview of treatment modalities available for orthopedic surgeons.
RECENT FINDINGS: The use of biologics as a primary treatment or adjunct to traditional management has shown encouraging results for the treatment of hip pain. Studies have demonstrated safety with minimal complications when using platelet rich plasma, hyaluronic acid, or stem cells to treat hip pain caused by osteoarthritis, femoroacetabular impingement syndrome, tendinopathy, or osteonecrosis of the femoral head. Several studies have been able to demonstrate meaningful clinical results that can improve treatment standards for hip pain; however, more work must be performed to better delineate the appropriate protocols, indications, and limitations of each modality. Recent advances have inspired renewed interest in biologics for patients with hip pain. We present a concise review of platelet rich plasma, hyaluronic acid, stem cells, and matrix metalloprotease inhibitors and their applicability to hip preservation surgery.
PubMed ID
33483876
ePublication
ePub ahead of print
